Intrexon traded at $8.30 this Thursday October 1st, decreasing $0.27 or 3.10 percent since the previous trading session. Looking back, over the last four weeks, Intrexon lost 18.33 percent. Over the last 12 months, its price rose by 149.10 percent. Looking ahead, we forecast Intrexon to be priced at 7.58 by the end of this quarter and at 7.10 in one year, according to Trading Economics global macro models projections and analysts expectations.
Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. The Company is offering a class of microbe-based biopharmaceuticals that enable the expression and local delivery of disease-modifying therapeutics. Precigen is using precision technology to target intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The Company also focused on studying life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications. The Company’s subsidiaries include PGEN Therapeutics, Inc., Precigen ActoBio, Inc., Exemplar Genetics, LLC and Trans Ova Genetics, L.C.